Lilly Adds Centrexion’s Non-Opioid Pain Therapy to Pipeline
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)
Published: 31 May-2019
DOI: 10.3833/pdr.v2019.i5.2430 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Eli Lilly has announced a license agreement to acquire the worldwide rights for CNTX-0290 from Centrexion Therapeutics, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS